Advertisement

Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation

  • Shuang Wu
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Yan-min Yang
    Correspondence
    Corresponding author: Tel: (+86) 10-8839-6294; fax: (+86) 10-8836-4591.
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Jun Zhu
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Huai-bin Wan
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Juan Wang
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Han Zhang
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
  • Xing-hui Shao
    Affiliations
    Emergency and Intensive Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
    Search for articles by this author
Published:December 29, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.12.027
      Anticoagulation in catheter ablation (CA) of atrial fibrillation (AF) is of paramount importance for prevention of thromboembolic events, and recent studies favor uninterrupted vitamin K antagonists (VKAs). We aimed to compare the efficacy and safety of new oral anticoagulants (NOACs) to uninterrupted VKAs for anticoagulation in CA by performing a meta-analysis. PubMed, EMBASE, the Cochrane Library, and Clinicaltrials.gov databases were searched for studies comparing NOACs with uninterrupted VKAs in patients who underwent CA for AF from January 1, 2000, to August 31, 2015. Odds ratio (OR) and Peto's OR (POR) were used to report for event rates >1% and <1%, respectively. A total of 11,686 patients with AF who underwent CA in 25 studies were included in this analysis. There was no significant difference between NOACs and uninterrupted VKAs in occurrence of stroke or transient ischemic attacks (POR 1.35, 95% CI 0.62 to 2.94) and major bleeding (POR 0.87, 95% CI 0.58 to 1.31), which were consistent in subgroup analysis of interrupted and uninterrupted NOACs. A lower risk of minor bleeding was observed with NOACs (OR 0.80, 95% CI 0.65 to 1.00), and no major differences were observed for the risk of thromboembolic events, cardiac tamponade or pericardial effusion requiring drainage, and groin hematoma. NOACs, whether interrupted preprocedure or not, were associated with equal rates of stroke or TIA and major bleeding complications and less risk of minor bleeding compared with uninterrupted VKAs in CA for AF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kok L.C.
        • Mangrum J.M.
        • Haines D.E.
        • Mounsey J.
        Cerebrovascular complication associated with pulmonary vein ablation.
        J Cardiovasc Electrophysiol. 2002; 13: 764-767
        • Nairooz R.
        • Sardar P.
        • Payne J.
        • Aronow W.S.
        • Paydak H.
        Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation.
        Int J Cardiol. 2015; 187: 426-429
        • Bassiouny M.
        • Saliba W.
        • Rickard J.
        • Shao M.
        • Sey A.
        • Diab M.
        • Martin D.O.
        • Hussein A.
        • Khoury M.
        • Abi-Saleh B.
        • Alam S.
        • Sengupta J.
        • Borek P.P.
        • Baranowski B.
        • Niebauer M.
        • Callahan T.
        • Varma N.
        • Chung M.
        • Tchou P.J.
        • Kanj M.
        • Dresing T.
        • Lindsay B.D.
        • Wazni O.
        Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
        Circ Arrhythm Electrophysiol. 2013; 6: 460-466
        • Kaiser D.W.
        • Streur M.M.
        • Nagarakanti R.
        • Whalen S.P.
        • Ellis C.R.
        Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
        J Interv Card Electrophysiol. 2013; 37: 241-247
        • Arshad A.
        • Johnson C.K.
        • Mittal S.
        • Buch E.
        • Hamam I.
        • Tran T.
        • Shaw R.E.
        • Musat D.
        • Preminger M.
        • Sichrovsky T.
        • Herweg B.
        • Shivkumar K.
        • Hummel J.
        • Steinberg J.S.
        Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study.
        Pacing Clin Electrophysiol. 2014; 37: 665-673
        • Ichiki H.
        • Oketani N.
        • Ishida S.
        • Iriki Y.
        • Okui H.
        • Maenosono R.
        • Namino F.
        • Ninomiya Y.
        • Miyata M.
        • Hamasaki S.
        • Tei C.
        The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
        Pacing Clin Electrophysiol. 2013; 36: 1328-1335
        • Kaseno K.
        • Naito S.
        • Nakamura K.
        • Sakamoto T.
        • Sasaki T.
        • Tsukada N.
        • Hayano M.
        • Nishiuchi S.
        • Fuke E.
        • Miki Y.
        • Nakamura K.
        • Yamashita E.
        • Kumagai K.
        • Oshima S.
        • Tada H.
        Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
        Circ J. 2012; 76: 2337-2342
        • Lakkireddy D.
        • Reddy Y.M.
        • Di Biase L.
        • Vanga S.R.
        • Santangeli P.
        • Swarup V.
        • Pimentel R.
        • Mansour M.C.
        • D'Avila A.
        • Sanchez J.E.
        • Burkhardt J.D.
        • Chalhoub F.
        • Mohanty P.
        • Coffey J.
        • Shaik N.
        • Monir G.
        • Reddy V.Y.
        • Ruskin J.
        • Natale A.
        Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation.
        J Am Coll Cardiol. 2012; 59: 1168-1174
        • Yamaji H.
        • Murakami T.
        • Hina K.
        • Higashiya S.
        • Kawamura H.
        • Murakami M.
        • Kamikawa S.
        • Hirohata S.
        • Kusachi S.
        Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation.
        Clin Drug Investig. 2013; 33: 409-418
        • Kim J.-S.
        • She F.
        • Jongnarangsin K.
        • Chugh A.
        • Latchamsetty R.
        • Ghanbari H.
        • Crawford T.
        • Suwanagool A.
        • Sinno M.
        • Carrigan T.
        • Kennedy R.
        • Saint-Phard W.
        • Yokokawa M.
        • Good E.
        • Bogun F.
        • Pelosi F.
        • Morady F.
        • Oral H.
        Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
        Heart Rhythm. 2013; 10: 483-489
        • Stepanyan G.
        • Badhwar N.
        • Lee R.J.
        • Marcus G.M.
        • Lee B.K.
        • Tseng Z.H.
        • Vedantham V.
        • Olgin J.
        • Scheinman M.
        • Gerstenfeld E.P.
        Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
        J Interv Card Electrophysiol. 2014; 40: 33-38
        • Bernard M.
        • Brabham W.
        • Netzler P.
        • Rowley C.
        • Gold M.
        • Leman R.
        • Sturdivant J.
        • Wharton J.M.
        • Cuoco F.
        Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin.
        J Am Coll Cardiol. 2013; 61: E276
        • Garcia L.I.
        • Ahuja K.
        • Mascarenhas M.A.
        • Aizer A.
        • Bernstein N.
        • Bernstein S.A.
        • Fowler S.J.
        • Holmes D.S.
        • Park D.S.
        • Chinitz L.
        The safety of dabigatran versus warfarin in patients undergoing atrial fibrillation ablation.
        Heart Rhythm. 2013; 10: S236-S237
        • Hirose S.
        • Miyamoto K.
        • Nakajima I.
        • Ishibashi K.
        • Okamura H.
        • Noda T.
        • Aiba T.
        • Kamakura S.
        • Kusano K.
        Discontinuation period and periprocedural events of novel oral anticoagulation in patients undergoing catheter ablation of atrial fibrillation.
        Eur Heart J. 2014; 35: 30
        • Shin D.G.
        • Kim T.H.
        • Park J.
        • Lee H.
        • Park J.K.
        • Uhm J.S.
        • Kim J.Y.
        • Joung B.
        • Lee M.H.
        • Pak H.N.
        Novel oral anticoagulants reduces preprocedural anticoagulation duration, but increases intra-procedural heparin requirement compared to uninterrupted warfarin in atrial fibrillation catheter ablation.
        Heart Rhythm. 2015; 12: S260
        • Toyama H.
        • Kumagai K.
        Relationship between oral anticoagulants and dose of heparin during procedure in patients undergoing catheter ablation of atrial fibrillation.
        Heart Rhythm. 2014; 11: S310-S311
        • Di Biase L.
        • Trivedi C.
        • Mohanty P.
        • Mohanty S.
        • Bai R.
        • Santangeli P.
        • Sanchez J.
        • Horton R.
        • Joseph Gallinghouse G.
        • Zagrodzky J.
        • Hao S.
        • Hongo R.
        • Beheiry S.
        • Lakkireddy D.R.
        • Reddy M.
        • Viles-Gonzalez J.F.
        • David Burkhardt J.
        • Natale A.
        Feasibility and safety of uninterrupted rivaroxaban in patients undergoing radiofrequency ablation for long standing persistent atrial fibrillation.
        Circulation. 2014; 130 (A16402)
        • Wunderlich C.
        • Christoph M.
        • Huo Y.
        • Forkmann M.
        • Gaspar T.
        • Salmas J.
        • Pohl M.
        • Mayer J.
        • Piorkowski C.
        Ablation of atrial fibrillation with uninterrupted NOAC treatment during ablation of atrial fibrillation is not associated with severe peri- and postprocedural complications.
        Europace. 2015; 17: iii234-iii236
        • Di Biase L.
        • Lakkireddy D.
        • Trivedi C.
        • Deneke T.
        • Martinek M.
        • Mohanty S.
        • Mohanty P.
        • Prakash S.
        • Bai R.
        • Reddy M.
        • Gianni C.
        • Horton R.
        • Bailey S.
        • Sigmund E.
        • Derndorfer M.
        • Schade A.
        • Mueller P.
        • Szoelloes A.
        • Sanchez J.
        • Al-Ahmad A.
        • Hranitzky P.
        • Gallinghouse G.J.
        • Hongo R.H.
        • Beheiry S.
        • Purerfellner H.
        • Burkhardt J.D.
        • Natale A.
        Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study.
        Heart Rhythm. 2015; 12: 1162-1168
        • Cappato R.
        • Marchlinski F.E.
        • Hohnloser S.H.
        • Naccarelli G.V.
        • Xiang J.
        • Wilber D.J.
        • Ma C.S.
        • Hess S.
        • Wells D.S.
        • Juang G.
        • Vijgen J.
        • Hugl B.J.
        • Balasubramaniam R.
        • De Chillou C.
        • Davies D.W.
        • Fields L.E.
        • Natale A.
        Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
        Eur Heart J. 2015; 36: 1805-1811
        • Dillier R.
        • Ammar S.
        • Hessling G.
        • Kaess B.
        • Pavaci H.
        • Buiatti A.
        • Semmler V.
        • Kathan S.
        • Hofmann M.
        • Lennerz C.
        • Kolb C.
        • Reents T.
        • Deisenhofer I.
        Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.
        Circ Arrhythm Electrophysiol. 2014; 7: 576-582
        • Kaess B.M.
        • Ammar S.
        • Reents T.
        • Dillier R.
        • Lennerz C.
        • Semmler V.
        • Grebmer C.
        • Bourier F.
        • Buiatti A.
        • Kolb C.
        • Deisenhofer I.
        • Hessling G.
        Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
        Am J Cardiol. 2015; 115: 47-51
        • Lakkireddy D.
        • Reddy Y.M.
        • Di Biase L.
        • Vallakati A.
        • Mansour M.C.
        • Santangeli P.
        • Gangireddy S.
        • Swarup V.
        • Chalhoub F.
        • Atkins D.
        • Bommana S.
        • Verma A.
        • Sanchez J.E.
        • Burkhardt J.D.
        • Barrett C.D.
        • Baheiry S.
        • Ruskin J.
        • Reddy V.
        • Natale A.
        Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
        J Am Coll Cardiol. 2014; 63: 982-988
        • Maddox W.
        • Kay G.N.
        • Yamada T.
        • Osorio J.
        • Doppalapudi H.
        • Plumb V.J.
        • Gunter A.
        • McElderry H.T.
        Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
        J Cardiovasc Electrophysiol. 2013; 24: 861-865
        • Nagao T.
        • Inden Y.
        • Yanagisawa S.
        • Kato H.
        • Ishikawa S.
        • Okumura S.
        • Mizutani Y.
        • Ito T.
        • Yamamoto T.
        • Yoshida N.
        • Hirai M.
        • Murohara T.
        Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation.
        Heart Rhythm. 2015; 12: 1972-1978
        • Nagao T.
        • Inden Y.
        • Shimano M.
        • Fujita M.
        • Yanagisawa S.
        • Kato H.
        • Ishikawa S.
        • Miyoshi A.
        • Okumura S.
        • Ohguchi S.
        • Yamamoto T.
        • Yoshida N.
        • Hirai M.
        • Murohara T.
        Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
        Pacing Clin Electrophysiol. 2015; 38: 155-163
        • Nagao T.
        • Inden Y.
        • Shimano M.
        • Fujita M.
        • Yanagisawa S.
        • Kato H.
        • Ishikawa S.
        • Miyoshi A.
        • Okumura S.
        • Ohguchi S.
        • Yamamoto T.
        • Yoshida N.
        • Hirai M.
        • Murohara T.
        Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
        Intern Med. 2015; 54: 1167-1173
        • Jackson Ii L.R.
        • Becker R.C.
        Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.
        J Thromb Thrombolysis. 2014; 37: 380-391
        • Sardar P.
        • Nairooz R.
        • Chatterjee S.
        • Wetterslev J.
        • Ghosh J.
        • Aronow W.S.
        Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.
        Am J Cardiol. 2014; 113: 1173-1177
        • Santarpia G.
        • De Rosa S.
        • Polimeni A.
        • Giampa S.
        • Micieli M.
        • Curcio A.
        • Indolfi C.
        Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
        PLoS One. 2015; 10: e0126512